

# Morton J Cowan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2916493/publications.pdf>

Version: 2024-02-01

76  
papers

4,823  
citations

126858

33  
h-index

95218

68  
g-index

84  
all docs

84  
docs citations

84  
times ranked

4482  
citing authors

#	ARTICLE	IF	CITATIONS
1	Poor T-cell receptor $\hat{I}^2$ repertoire diversity early posttransplant for severe combined immunodeficiency predicts failure of immune reconstitution. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1113-1119.	1.5	8
2	Quantitative brain MRI morphology in severe and attenuated forms of mucopolysaccharidosis type I. <i>Molecular Genetics and Metabolism</i> , 2022, 135, 122-132.	0.5	5
3	Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Venocclusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 196-202.	0.6	12
4	Granulocyte Transfusions in Patients with Chronic Granulomatous Disease Undergoing Hematopoietic Cell Transplantation or Gene Therapy. <i>Journal of Clinical Immunology</i> , 2022, 42, 1026-1035.	2.0	3
5	Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC. <i>Blood</i> , 2022, 140, 685-705.	0.6	26
6	Lentivector cryptic splicing mediates increase in CD34+ clones expressing truncated HMGA2 in human X-linked severe combined immunodeficiency. <i>Nature Communications</i> , 2022, 13, .	5.8	19
7	Unknown cytomegalovirus serostatus in primary immunodeficiency disorders: A new category of transplant recipients. <i>Transplant Infectious Disease</i> , 2021, 23, e13504.	0.7	2
8	Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers. <i>Journal of Clinical Immunology</i> , 2021, 41, 38-50.	2.0	36
9	The Relationship Between Busulfan Exposure and Achievement of Sustained Donor Myeloid Chimerism in Patients with Non-Malignant Disorders. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 258.e1-258.e6.	0.6	3
10	Successful SCID gene therapy in infant with disseminated BCG. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 993-995.e1.	2.0	3
11	Expectations and experience: Parent and patient perspectives regarding treatment for Severe Combined Immunodeficiency (SCID). <i>Clinical Immunology</i> , 2021, 229, 108778.	1.4	0
12	JSP191 As a Single-Agent Conditioning Regimen Results in Successful Engraftment, Donor Myeloid Chimerism, and Production of Donor Derived Na <sup>+</sup> ve Lymphocytes in Patients with Severe Combined Immunodeficiency (SCID). <i>Blood</i> , 2021, 138, 554-554.	0.6	5
13	Extended Follow-up After Hematopoietic Cell Transplantation for $\hat{I}^2$ Deficiency with Disseminated Mycobacterium avium Infection. <i>Journal of Clinical Immunology</i> , 2020, 40, 248-250.	2.0	1
14	Reduced Toxicity Conditioning for Nonmalignant Hematopoietic Cell Transplants. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1646-1654.	2.0	9
15	Adenosine Deaminase (ADA)â€“Deficient Severe Combined Immune Deficiency (SCID) in the US Immunodeficiency Network (USIDNet) Registry. <i>Journal of Clinical Immunology</i> , 2020, 40, 1124-1131.	2.0	19
16	Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. <i>Blood</i> , 2020, 135, 2094-2105.	0.6	87
17	Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey. <i>Frontiers in Immunology</i> , 2020, 11, 239.	2.2	57
18	Allograft and patient survival after sequential HSCT and kidney transplantation from the same donorâ€“A multicenter analysis. <i>American Journal of Transplantation</i> , 2019, 19, 475-487.	2.6	14

#	ARTICLE	IF	CITATIONS
19	Quality of Life of Patients with Wiskott Aldrich Syndrome and X-Linked Thrombocytopenia: a Study of the Primary Immune Deficiency Consortium (PIDTC), Immune Deficiency Foundation, and the Wiskott-Aldrich Foundation. <i>Journal of Clinical Immunology</i> , 2019, 39, 786-794.	2.0	11
20	Newborn Screening for Severe Combined Immunodeficiency and T-cell Lymphopenia in California, 2010â€“2017. <i>Pediatrics</i> , 2019, 143, .	1.0	148
21	Hematopoietic stem cell transplantation for CD40 ligand deficiency: Results from an EBMT/ESID-IEWP-SCETIDE-PIDTC study. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2238-2253.	1.5	60
22	Low Exposure Busulfan Conditioning to Achieve Sufficient Multilineage Chimerism in Patients with Severe Combined Immunodeficiency. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1355-1362.	2.0	22
23	Supporting caregivers during hematopoietic cell transplantation for children with primary immunodeficiency disorders. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2271-2278.	1.5	9
24	Psychosocial services for primary immunodeficiency disorder families during hematopoietic cell transplantation: A descriptive study. <i>Palliative and Supportive Care</i> , 2019, 17, 409-414.	0.6	2
25	The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018). <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 405-407.	1.5	64
26	Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 322-328.e10.	1.5	79
27	Donor lymphocyte infusion and methotrexate for immune recovery after Tâ€“cell depleted haploidentical transplantation. <i>American Journal of Hematology</i> , 2018, 93, 169-178.	2.0	9
28	Advances and highlights in primary immunodeficiencies in 2017. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1041-1051.	1.5	7
29	SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. <i>Blood</i> , 2018, 132, 1737-1749.	0.6	128
30	Application of a radiosensitivity flow assay in a patient with DNA ligase 4 deficiency. <i>Blood Advances</i> , 2018, 2, 1828-1832.	2.5	13
31	B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation. <i>Blood</i> , 2018, 131, 2967-2977.	0.6	37
32	Outcome of domino hematopoietic stem cell transplantation in human subjects: An international case series. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1628-1631.e4.	1.5	1
33	Evaluation of Preâ€“Hematopoietic Cell Transplantation (HCT) Brain MRI and Neurologic Complications of Pediatric Patients Undergoing HCT for Hematologic Malignancies. <i>Journal of Pediatric Oncology Nursing</i> , 2017, 34, 65-73.	1.5	0
34	Transplacental maternal engraftment and posttransplantation graft-versus-host disease in children with severe combined immunodeficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 628-633.e10.	1.5	30
35	Treatment of infants identified as having severe combined immunodeficiency by means of newborn screening. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 733-742.	1.5	73
36	Recommendations for Screening and Management of Late Effects in Patients with Severe Combined Immunodeficiency after Allogeneic Hematopoietic Cell Transplantation: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1229-1240.	2.0	44

#	ARTICLE	IF	CITATIONS
37	Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1342-1349.	2.0	50
38	Genotype, Phenotype and T Cell Counts at One Year Predict Survival and Long Term Immune Reconstitution after Transplantation in Severe Combined Immune Deficiency (SCID)â€”The Primary Immune Deficiency Treatment Consortium (PIDTC). <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S133-S134.	2.0	4
39	Reticular dysgenesis: international survey on clinical presentation, transplantation, and outcome. <i>Blood</i> , 2017, 129, 2928-2938.	0.6	31
40	Immune reconstitution and survival of 100 SCID patients postâ€”hematopoietic cell transplant: a PIDTC natural history study. <i>Blood</i> , 2017, 130, 2718-2727.	0.6	212
41	Long term outcomes of severe combined immunodeficiency: therapy implications. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 1029-1040.	1.3	22
42	Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1701-1713.	2.0	32
43	Opening Marrow Niches in Patients Undergoing Autologous Hematopoietic Stem Cell Gene Therapy. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 809-822.	0.9	8
44	The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Defining the Unique Late Effects of Children Undergoing Hematopoietic Cell Transplantation for Immune Deficiencies, Inherited Marrow Failure Disorders, and Hemoglobinopathies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 24-29.	2.0	33
45	Neurologic eventâ€”free survival demonstrates a benefit for SCID patients diagnosed by newborn screening. <i>Blood Advances</i> , 2017, 1, 1694-1698.	2.5	14
46	Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56bright NKG2A+++ Cells, and Yet Display Increased Degranulation and Higher Perforin Content. <i>Frontiers in Immunology</i> , 2017, 8, 798.	2.2	41
47	Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. <i>Lancet Haematology</i> , 2016, 3, e526-e536.	2.2	197
48	Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant <i>BCL11B</i> . <i>New England Journal of Medicine</i> , 2016, 375, 2165-2176.	13.9	104
49	Devouring the Hematopoietic Stem Cell: Setting the Table for Marrow Cell Transplantation. <i>Molecular Therapy</i> , 2016, 24, 1892-1894.	3.7	3
50	Primary Immune Deficiency Treatment Consortium (PIDTC) update. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 375-385.	1.5	33
51	Unrelated Hematopoietic Cell Transplantation in a Patient with Combined Immunodeficiency with Granulomatous Disease and Autoimmunity Secondary to RAG Deficiency. <i>Journal of Clinical Immunology</i> , 2016, 36, 725-732.	2.0	19
52	Severe, persistent, and fatal Tâ€”cell immunodeficiency following therapy for infantile leukemia. <i>Pediatric Blood and Cancer</i> , 2016, 63, 2046-2049.	0.8	12
53	Radiation-sensitive severe combined immunodeficiency: The arguments for and against conditioning before hematopoietic cell transplantationâ€”what to do?. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 1178-1185.	1.5	63
54	Successful newborn screening for SCID in the Navajo Nation. <i>Clinical Immunology</i> , 2015, 158, 29-34.	1.4	48

#	ARTICLE	IF	CITATIONS
55	Neurocognition across the spectrum of mucopolysaccharidosis type I: Age, severity, and treatment. <i>Molecular Genetics and Metabolism</i> , 2015, 116, 61-68.	0.5	59
56	Population Pharmacokinetics of Busulfan in Pediatric and Young Adult Patients Undergoing Hematopoietic Cell Transplant. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 236-245.	1.0	67
57	Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency. <i>Journal of Clinical Investigation</i> , 2015, 125, 4135-4148.	3.9	159
58	Newborn Screening for Severe Combined Immunodeficiency in 11 Screening Programs in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 729.	3.8	586
59	Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: The Primary Immune Deficiency Treatment Consortium experience. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1092-1098.	1.5	301
60	Primary Immune Deficiency Treatment Consortium (PIDTC) report. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 335-347.e11.	1.5	65
61	Transplantation Outcomes for Severe Combined Immunodeficiency, 2000-2009. <i>New England Journal of Medicine</i> , 2014, 371, 434-446.	13.9	594
62	Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 935-943.e15.	1.5	82
63	Survey on retransplantation criteria for patients with severe combined immunodeficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 597-599.	1.5	5
64	SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID. <i>Blood</i> , 2014, 123, 281-289.	0.6	150
65	The Natural History of Children with Severe Combined Immunodeficiency: Baseline Features of the First Fifty Patients of the Primary Immune Deficiency Treatment Consortium Prospective Study 6901. <i>Journal of Clinical Immunology</i> , 2013, 33, 1156-1164.	2.0	100
66	Effect of Weight and Maturation on Busulfan Clearance in Infants and Small Children Undergoing Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1608-1614.	2.0	69
67	Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. <i>Blood</i> , 2011, 118, 1675-1684.	0.6	296
68	Hematopoietic Stem Cell Transplantation for Severe Combined Immunodeficiency Diseases. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 73-80.	2.0	22
69	Megadose CD34 + Cell Grafts Improve Recovery of T Cell Engraftment but not B Cell Immunity in Patients with Severe Combined Immunodeficiency Disease Undergoing Haplocompatible Nonmyeloablative Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1125-1133.	2.0	47
70	Effects of B7.2 <sup>-/-</sup> Mature Dendritic Cells on Tolerance Induction to Alloantigens in Fetal Mice Following In Utero Transplantation with Lineage Depleted Bone Marrow. <i>Blood</i> , 2004, 104, 2134-2134.	0.6	0
71	A new gene involved in DNA double-strand break repair and V(D)J recombination is located on human chromosome 10p. <i>Human Molecular Genetics</i> , 2000, 9, 583-588.	1.4	85
72	Siblings' Perceptions of the Bone Marrow Transplantation Process. <i>Journal of Psychosocial Oncology</i> , 1997, 15, 81-105.	0.6	34

#	ARTICLE	IF	CITATIONS
73	Maternal mosaicism for a novel interleukin-2 receptor gamma-chain mutation causing X-linked severe combined immunodeficiency in a Navajo kindred. <i>Journal of Clinical Immunology</i> , 1997, 17, 29-33.	2.0	26
74	Microgranulomatous aspergillosis after shoveling wood chips: Report of a fatal outcome in a patient with chronic granulomatous disease. <i>American Journal of Industrial Medicine</i> , 1992, 22, 411-418.	1.0	19
75	ASPERGILLUS PNEUMONIA IN CHRONIC GRANULOMATOUS DISEASE: RECURRENCE AND LONG-TERM OUTCOME. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1982, 71, 915-917.	0.7	15
76	Intermittent ataxia and immunodeficiency with multiple carboxylase deficiencies: A biotin-responsive disorder. <i>Annals of Neurology</i> , 1980, 8, 544-547.	2.8	55